Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Waylivra in Type 2 Diabetes and Hypertriglyceridemia
NCT01647308Phase 2Terminated
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jul 2012
- Primary completion
- Jan 2014
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of volanesorsen in type 2 diabetes mellitus (T2DM) and hypertriglyceridemia, sponsored by Ionis Pharmaceuticals. Primary endpoint: Total apolipoprotein C-III at 91 days. Started Jul 2012; status: terminated.
02
Drugs
volanesorsen
03
Conditions
type 2 diabetes mellitus (T2DM)hypertriglyceridemia
Beyond the preview
Go deeper on NCT01647308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01647308.